Overview

RE-ELECT. Dabigatran vs Warfarin in AF Patients With T2DM and CKD

Status:
Recruiting
Trial end date:
2022-05-01
Target enrollment:
Participant gender:
Summary
Kidney function in patients with atrial fibrillation (AF) is tending to decline over a time which is clearly demonstrated in clinical studies. Renal impairment is a risk factor for stroke, its progression is associated with unfavorable prognosis. So preserving kidney function should be considered as a one of priorities when choosing treatment strategies which is especially important in patients with existing chronic kidney disease (CKD) or in patients who have risk of its development. This is especially relevant for the patients with type 2 diabetes mellitus (T2DM) and with CKD who can be considered as a group of risk for rapid kidney function decline.
Phase:
Phase 4
Details
Lead Sponsor:
Irina Ermolaeva
Treatments:
Dabigatran
Warfarin